Drug Trial Radar · NCT05347069
Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,890
Planned (sponsor's estimate)
Start
Jun 14, 2022
Primary completion
Mar 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Takeshi MorimotoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety aspirin in patients with chronic coronary syndromes without revascularization.
Conditions
- Stable Angina Pectoris
- Coronary Artery Disease
- Ischemic Heart Disease
Interventions
AspirinDrug
Aspirin 100 mg/day
No aspirinDrug
No aspirin administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite cardiovascular eventsTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kyoto University Hospital
Kyoto, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.